Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04400552
Other study ID # IMU R204/2017
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 26, 2018
Est. completion date June 30, 2021

Study information

Verified date August 2021
Source International Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the effectiveness of perioperative oral nutrition supplementation (ONS) on nutritional status in malnourished cancer patients undergoing elective surgery. The hypothesis is pre-operative ONS feeding in malnourished surgical cancer patients is effective on improving nutritional status. An extended period of 3 months post-operative ONS feeding is effective on improving nutritional status as compared to ONS feeding post-operatively during hospital stay only. Perioperative feeding is effective on improving secondary outcomes such as sleep quality, post-operative complications and length of hospital stay.


Description:

The main objective of this study is to evaluate the effectiveness of perioperative oral nutrition supplementation (ONS) on nutritional status in malnourished cancer patients undergoing elective surgery. The specific objectives are: 1. To evaluate the baseline nutritional status of cancer patients undergoing elective surgery 2. To evaluate the effectiveness of pre-operative ONS feeding on nutritional status in malnourished surgical cancer patients 3. To evaluate the effectiveness of an extended 3 months post-operative ONS feeding after discharge versus ONS feeding only post-operatively during hospital on nutritional status 4. To evaluate secondary outcomes of perioperative feeding such as sleep quality, post-operative complications and length of hospital stay Study Design: This is a randomised-controlled-open label-parallel group(s)-trial which will be conducted on malnourished cancer patients undergoing elective surgery. Study duration: The participation duration for each participant is 4 months. The completion of the study will take around 30 months.


Recruitment information / eligibility

Status Completed
Enrollment 91
Est. completion date June 30, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group 25 Years to 65 Years
Eligibility Inclusion Criteria: - Male or female from all ethnicity - 25 to 65 years - BMI not less than 18.0 kg/m² - Cancer patients who are confirmed with elective surgery whose co-morbidities are stabilized based on the ASA Physical Status Classification System ASA Class 1 and 2 - Fulfil at least two characteristics of AND/ ASPEN Diagnosis of Malnutrition These characteristics are insufficient energy intake, weight loss, loss of muscle mass, loss of subcutaneous fat, localized or generalized fluid accumulation and diminished functional status as measured by handgrip strength. Exclusion Criteria: - Patients who require enteral or parenteral feeding - Pregnant or lactating - On chemotherapy or radiotherapy - Total gastrectomy or ileostomy - Metastasized cancer, upper gastrointestinal cancer, terminal diseases, decompensated liver or renal disease, major concurrent metabolic problem such as uncontrolled diabetes, dementia - On regular steroids prescription

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
ONS Pre-op + ONS Post-op
Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively and post-operatively up to participants being discharged from the hospital.
ONS Pre-op + ONS Post-op + ONS Post-op 3 months
Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively, post-operatively up to participants being discharged from the hospital and an extended oral nutrition supplementation post-operatively up to 3 months.
Usual intake Pre-op + ONS Post-op
Participants will follow a meal plan of 2000 kcal / day using conventional foods for 14 days pre-operatively and consume oral nutrition supplementation (ONS) in addition to normal diet post-operatively up to participants being discharged from the hospital

Locations

Country Name City State
Malaysia International Medical University Kuala Lumpur

Sponsors (2)

Lead Sponsor Collaborator
International Medical University Kotra Pharma (M) Sdn Bhd

Country where clinical trial is conducted

Malaysia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in body weight Anthropometry measurement Change from baseline body weight at 4 months
Primary Change in body mass index (BMI) Anthropometry measurement Change from baseline body mass index (BMI) at 4 months
Primary Change in serum albumin level Serum albumin is an indicator of protein stores to assess nutritional status Change from baseline serum albumin level at 4 months
Primary Change in serum pre-albumin level Serum pre-albumin is an indicator of protein stores to assess nutritional status Change from baseline serum pre-albumin level at 4 months
Secondary Change in handgrip force Handgrip force is a measure of handgrip strength by dynamometer Change from baseline handgrip force at 4 months
Secondary Change in muscle mass Muscle mass reported in kilogram is measured by bioelectrical impedance analyser Change from baseline muscle mass at 4 months
Secondary Change in fat mass Fat mass reported in kilogram is measured by bioelectrical impedance analyser Change from baseline fat mass at 4 months
Secondary Change in serum transferrin level Serum transferrin is a measure of nutritional status Change from baseline serum transferrin level at 4 months
Secondary Change in hemoglobin level Serum hemoglobin is a measure of nutritional status Change from baseline hemoglobin level at 4 months
Secondary Change in high sensitivity c-reactive protein (HsCRP) level High sensitivity c-reactive protein (HsCRP) is a measure of inflammatory status Change from baseline high sensitivity c-reactive protein (HsCRP) level at 4 months
Secondary Change in Interleukin-6 (IL-6) Interleukin-6 (IL-6) is a measure of inflammatory status Change from baseline Interleukin-6 (IL-6) at 4 months
Secondary Change in salivary cortisol level Salivary cortisol level is a biological marker of stress reaction Change from baseline salivary cortisol level at 4 months
Secondary Change in energy intake Energy intake reported in calories is a dietary measure to assess nutritional status Change from baseline energy intake at 4 months
Secondary Change in protein intake Protein intake reported in gram is a dietary measure to assess nutritional status Change from baseline protein intake at 4 months
Secondary Change in Pittsburgh Sleep Quality Index (PSQI) scores Pittsburgh Sleep Quality Index (PSQI) scores range from 0-42.Higher scores indicate poorer sleep quality Change from baseline Pittsburgh Sleep Quality Index (PSQI) scores at 4 months
Secondary Presence of post-surgical complications Post-surgical complications are indicated by presence of wound infection, chest infection and use of antibiotics, responses are either yes or no Change from baseline post-surgical complications at 3 months
Secondary Length of hospital stay Number of days participants are admitted into the hospital Up to 5 days
See also
  Status Clinical Trial Phase
Withdrawn NCT03285607 - MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer Phase 1
Completed NCT02225470 - Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes Phase 3
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2
Completed NCT01271738 - Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer N/A
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Completed NCT01980823 - Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer Early Phase 1
Completed NCT02658708 - Bright Light on Fatigue in Women Being Treated for Breast Cancer Phase 1
Completed NCT02891681 - Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment N/A
Completed NCT05584644 - A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT03084536 - PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery Phase 2
Terminated NCT02907918 - Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer Phase 2
Completed NCT03007979 - Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer Phase 2
Terminated NCT02462200 - Shave Margins in Breast Conservation Therapy Phase 2
Completed NCT03592121 - Study to Investigate the Effect of AB-101 in Breast Cancer Survivors Early Phase 1
Terminated NCT02642094 - Aging Mammary Stem Cells and Breast Cancer Prevention Phase 2
Active, not recruiting NCT04855552 - Telehealth Weight Loss Program for Breast Cancer Survivors N/A
Active, not recruiting NCT05364450 - Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors N/A
Completed NCT03494400 - Aerobic Training in Treatment for Breast Cancer N/A
Terminated NCT02375048 - Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI Phase 2